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ABSTRACT
Objectives: The aim of the study was to analyze the correlation of multiples of the normal median of PAPP-A, free β-hCG 
levels and nuchal translucency values in prenatal, first trimester screening of trisomy 21 in pregnant women.
Material and methods: 251 pregnant women underwent antenatal screening at 11–13+6 weeks of pregnancy which was 
composed of the measurement of free β-human chorionic gonadotropin (β-hCG) and pregnancy-associated plasma protein 
(PAPP-A) levels in the maternal serum and an ultrasound assessment of nuchal translucency (NT). The pregnant women 
with a high risk of trisomy 21 (≥ 1:300) were given amniocentesis to verify fetal defects. There were 217 cases of normal 
fetal karyotype and 34 cases of trisomy 21. PAPP-A, β-hCGMoM and NT values were analyzed for the predefined ranges.
Results: 85% cases of trisomy 21 had elevated free β-hCGMoM (> 1.5) and only 53% of these had a PAPP-AMoM result 
below 0.5 (p < 0.05). Analysis of NT in selected ranges of β-hCG (> 1.5) and PAPP-AMoM (< 0.05), which are typical for Down 
Syndrome values, showed that not all fetuses with Down Syndrome presented with an increased NT. Respectively 44.15% 
and 26.5% of fetuses presented with increased NT. Characteristic for trisomy 21, a correlation with all 1st trimester screening 
tests’ parameters occurred in only 23.5% of cases. In 53% of cases the results were atypical.
Conclusions: The PAPP-A and β-hCG values in the selected MoM ranges did not shown a correlation to the NT measurement, 
therefore they are independent factors in the diagnosis of trisomy 21. Simultaneous biochemical and ultrasound testing is 
an indispensable condition for prenatal diagnosis of trisomy 21 in the 1st trimester of pregnancy. 
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INTRODUCTION
Prenatal screening that include non-invasive diagnostic 
tests enable assessment of the risk of fetal chromosomal 
aberrations and may reduce the use of invasive procedures 
associated with the 0.5–1.0% risk of miscarriage [1–4]. Since 
the 1990s, measuring maternal serum free beta human chori-
onic gonadotropin (β-hCG) and pregnancy associated plasma 
protein (PAPP-A) levels has been included in first-trimester 
prenatal screening carried out at 11–13+6 weeks of gestation 
alongside a fetal ultrasound assessment that includes nuchal 
translucency (NT) measurement. This, according to different 
authors, enables the detection of approximately 80–90% of 
all trisomy 21 cases [1, 2, 5–11]. The measured concentrations 
of either PAPP-A or free β-hCG are converted into the multi-
ples of the median (MoM) appropriate to the gestational age 
of each pregnancy. The MoM value is obtained by dividing 
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an individual’s marker concentration by the median level of 
that marker for the entire population at the same gestational 
age in that laboratory. In a healthy pregnancy, the maternal 
serum PAPP-A level increases exponentially, whereas the 
free β-hCG level drops, after an initial increase, in the period 
between 10 and 14 gestational weeks [12]. According to FMF 
and Polish Society of Gynecologists and Obstetricians recom-
mendations, a PAPP-A MoM below 0.5, free β-hCG MoM above 
1.5, and a nuchal translucency increase in weeks 11–13+6 of 
gestation are typical of fetal trisomy 21 [7–11, 13–15].
The debate on the utility of combined ultrasound and 
biochemistry testing and the role of such screening in de-
tecting chromosomal aberrations has been ongoing for 
over 20 years. Therefore, a detailed analysis was conceived 
to assess the association between the individual parameters 
and to determine whether the magnitude of PAPP-A level 
reduction and free β-hCG level elevation are of clinical sig-
nificance in Down Syndrome risk calculation. 
Aim
The aim of the study was to analyze the correlation in 
multiples of the normal median of biochemical parameters 
in maternal serum — PAPP-A and free β-hCG — as well as 
nuchal translucency values in the 11–13+6 weeks of gesta-
tion in patients with cytogenetically confirmed trisomy 21.
MATERIAL AND METHODS
The study included a group of 251 pregnant women 
aged 18 to 46 years (mean age of 35.9 years), with a mean BMI 
of 23.44, who were patients at the Ultrasonography and 
Prenatal Imaging Clinic of the Gynaecology and Obstet-
rics Hospital of Poznan University of Medical Sciences. All 
women with an increased risk of trisomy 21 (≥ 1:300) in 
the 1st trimester screening test (double test), had genetic 
amniocentesis to assess the fetal karyotype, in accordance 
with recommendations of the Ultrasonography Division of 
the Polish Society of Gynecologists and Obstetricians.
Assessment of the occurrence of chromosomal aberrations 
was carried out using the routine antenatal scan at 11–13+6 ges-
tational weeks, which consisted of ultrasound fetal assessment 
with a maternal serum assay of PAPP-A and free β-hCG.
Ultrasound examination included assessment of the risk 
markers of the most common chromosomal aberrations 
(trisomy 21, 18, 13) — crown-rump length (CRL) of 45–85 mm, 
nuchal translucency (NT), fetal heart rate, and blood flow in 
the ductus venosus with fetal anatomy and chorion [1, 2, 16].
Maternal serum concentrations of free β-hCG and 
PAPP-A were determined using an immunofluorometric 
assay on the Delfia Xpress analyzer (Perkin-Elmer Life and 
Analytical Sciences, Waltham, USA). The reaction surface was 
coated with specific antibodies directed against the respec-
tive PAPP-A and β-hCG antigen determinant. Then, antibod-
ies to other antigenic determinants of the parameters were 
studied, labeled with fluorochrome (Europium), and added 
to be able to read the concentrations of the determined 
parameters. The resulting complex was read at 612 nm.
The risk of trisomy 21 was calculated based on the meas-
ured biochemical markers and ultrasound parameters using 
©2000–2016 Astraia software (Astraia Software Gmbh, Oc-
camstr. 20, 80802 Munich, Germany) [1, 13, 16].
Participants with an elevated risk of trisomy 21 (< 1:300) 
were offered amniocentesis in line with the recommenda-
tion of the Ultrasonography Division of the Polish Society of 
Gynecologists and Obstetricians. It consisted of abdominal 
collection of approximately 20 mL of amniotic fluid, then 
amniocytes — amniotic fluid cells were cultured in a special 
media. In the cytogenic preparations obtained after the 
culture, metaphases colored by the G-band method were 
analyzed to assess the karyotype.
Patients were sub-divided into two groups according to 
the occurrence of fetal defects: group I — pregnant women 
with a normal karyotype; and group II — pregnant women 
with trisomy 21 in fetuses.
In both groups a detailed analysis of the PAPP-A and free 
β-hCG MoM values was carried out to determine their corre-
lation with the risk of trisomy 21. The following PAPP-A MoM 
ranges were determined: 0.001–0.500; 0.501–0.900; and 
above 0.901. Similarly, the following free β-hCG MoM ranges 
were determined: 0.001–1.000; 1.001–1.500; 1.501–2.000; 
and above 2.000.
The nuchal translucency (NT) values of the fetuses in 
the group with trisomy 21, that were classified into the pre-
defined ranges of 1.0–2.0 mm, 2.1–3.0 mm, 3.1–5.0 mm, 5.1–
8.0 mm, and above 8.1 mm, were analyzed for PAPP-A MoM 
of 0.001–0.500 and above 0.500 and free β-hCG MoM of 
0.001–1.500 and above 1.500.
Statistical analysis was carried out using the PQStat 
bundle. Normality of distribution was verified using the Kol-
mogorov–Smirnov test, Lillefors test and Shapiro-Wilk test. 
The ROC analysis of the assessed classifiers (PAPP-A MoM and 
β-hCG MoM) enabled us to distinguish between participants 
with fetal trisomy 21 and those with normal fetal karyotype.
RESULTS 
Of all patients who underwent cytogenetic evaluation, 
217 were diagnosed with normal fetal karyotype and 34 cases 
were diagnosed with trisomy 21. In the group with normal kar-
yotype results, the patients ≥ 35 years old accounted for 68.8% 
of the trisomy 21 cases and 31.2% were < 35 years. The age 
distribution was similar in the group with fetal trisomy 21, 
with 67.6% of the women aged ≥ 35 years and 32.3% 
aged < 35 years. In the study group overall, the age of the preg-
nant women had no significance on the results of the study 
and this parameter was discarded as an assessment criterion.
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The mean β-hCG MoM = 2.894, with SD ± 1.665 in 
34 cases of fetal trisomy 21, was higher than in the group 
with normal karyotype results β-hCG MoM = 1.979, with 
SD ± 1.569 (p < 0.05).
A detailed analysis of free β-hCG MoM demonstrated that 
the maternal serum free β-hCG MoM was above 1.5 in most of 
the fetal trisomy 21 cases (85.28%). At the same time, 58.53% 
of the participants with free β-hCG MoM above 1.5 had nor-
mal fetal karyotype, including 43.78% of the cases with free 
β-hCG MoM above 2.0 (64.70% for fetuses with trisomy 21).
Cases of confirmed fetal trisomy 21 constituted only a small 
part (14.7%) of the subgroup with free β-hCG MoM below 
1.5. 41.50% were cases with normal fetal karyotype (Fig. 1).
The mean PAPP-A MoM in cases of confirmed fetal triso-
my 21 was significantly lower than in cases of fetal euploidy 
(0.539 ± 0.281 vs. 0.691 ± 0.45, p < .05).
The PAPP-A MoM analysis demonstrated the largest 
proportion (52.94%) of trisomy 21 cases in a subgroup with 
PAPP-A MoM ranging between 0.001 and 0.500. At the same 
time, the euploidy cases comprised 36.87% of that subgroup. 
A subgroup with PAPP-A MoM above 0.501 consisted 
of trisomy 21 cases in 47.05% of the subjects and euploidy 
cases in 63.13% of the subjects (Fig. 2).
The ROC analysis for the assessed classifiers (PAPP-A MoM 
and β-hCG MoM) enabled us to distinguish between par-
ticipants with fetal trisomy 21 and those with normal fetal 
karyotype (Fig. 3 and 4).
The cut-off value of PAPP-A MoM was 0.463. Its sen-
sitivity and specificity were 70.8% and 50%, respectively. 
A decrease of PAPP-A MoM below the cut-off value increases 
the marker’s sensitivity and the likelihood of trisomy 21. The 
cut-off value of free β-hCGMoM was 2.17. Its sensitivity and 
specificity were 75.1% and 52.8%, respectively. An increase 
in the free β-hCG MoM above the cut-off value increases the 
likelihood of trisomy 21 (Tab. 1).
In cases of confirmed fetal trisomy 21, nuchal translu-
cency was significantly higher than in cases of euploidy 
(3.9 mm ± 1.893 vs. 2.2 mm ± 0.938). 
The next stage was to analyze the fetal nuchal trans-
lucency in selected PAPP-A MoM ranges. It was demon-
strated that among the cases of known fetal trisomy 21, only 
26.5% of fetuses had NT over 3.1 mm if the maternal serum 
PAPP-A MoM fell within the range 0.001-0.500.
Figure 4. ROC curve - sensitivity and specificity of β-hCG MoM to 
distinguish between cases of trisomy 21 and euploidy
Figure 1. Cases of fetal euploidy and trisomy 21 in the analyzed free 
β-hCG MoM ranges
Figure 2. Cases of fetal euploidy and trisomy 21 in the analyzed 
PAPP-A MoM ranges
Figure 3. ROC curve - sensitivity and specificity of PAPP-A MoM to 
distinguish between cases of trisomy 21 and euploidy
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Also, 26.5% of fetuses with known trisomy 21 and ma-
ternal serum PAPP-A MoM below 0.500 did not present with 
increased NT; instead, PAPP-A MoM was the only aneuploidy 
indicator. 
Furthermore, 17.66% of fetuses with known trisomy 21 
and maternal serum PAPP-A MoM above 0.500 did not pre-
sent with increased NT as compared with 29.4% of fetuses 
with NT over 3.1 mm in the same subgroup. Among these 
cases, only the increased NT sub-set was indicative of Down 
Syndrome risk (Fig. 5).
Among the confirmed cases of fetal trisomy 21, in a sub-
group of participants with free β-hCG MoM over 1.5, an NT 
increase over 3.1 mm was demonstrated in 44.15% of cases, 
as compared with 41.2% of cases with an NT below 3.0 mm. 
On the other hand, in a subgroup of participants with free 
β-hCGMoM below 1.5, an NT increase over 3.1 mm was 
demonstrated in 11.8% of cases, as compared with 2.94% 
of cases with an NT below 3.0 mm (Fig. 6).
The combined analysis of biochemical parameters 
and nuchal translucency in the group with fetal tri-
somy 21 showed that 23.5% of pregnant women had 
PAPP-A MoM < 0.5 and > 1.5 β-hCG MoM with an increased 
NT. Also, 23.5% of cases of this group presented with typical 
trisomy 21 biochemical parameters without an NT increase.
Among the confirmed trisomy 21 cases, there were 
18 cases (53%) of atypical PAPP-A and free β-hCG MoM 
values, combined with the absence of simultaneous 
PAPP-A MoM reduction and free β-hCG MoM elevation, 
which typically indicates a high risk of Down Syndrome. 
A combination of normal PAPP-A MoM (of about 1.0) and 
elevated free β-hCGMoM (above 1.5) was shown in 38.2% 
(n = 13) of known trisomy 21 cases; and in addition, 61.5% 
of these fetuses had an increased nuchal translucency. 
A combination of normal free β-hCG MoM and reduced 
PAPP-A MoM (below 0.5) was shown in 8.8% of known tri-
somy 21 cases; and in addition, 66.7% of these fetuses had 
an increased nuchal translucency. The two remaining cases 
of trisomy 21 had reduced PAPP-A MoM combined with 
reduced free β-hCGMoM, and normal PAPP-A MoM com-
bined with reduced free β-hCGMoM, respectively. Nuchal 
translucency was increased in both cases. (Tab. 2 and 3).
The presented results prove that the biochemical values 
and nuchal translucency, as parameters, are independent 
of each other in the diagnosis of trisomy 21.
DISCUSSION
Non-invasive, first-trimester prenatal screening encom-
passing a combination of maternal serum biochemistry assays 
(free β-hCG and PAPP-A) and ultrasound-assessed nuchal trans-
lucency (NT) enables accurate identification of approximately 
90% of chromosomal abnormalities with 5% false positive 
results [7, 8, 13, 16]. The results of individual tests may not 
always correlate with each other as per the current standards; 
however, the ultimate output will indicate an increased risk of 
aneuploidy. We have observed this in our sample of known 
trisomy 21 cases. The preliminary data analysis showed no 
significant differences between the mean free β-hCG and 
PAPP-A MoM levels obtained in our sample of known trisomy 
21 cases and those reported by other authors [8, 9, 12, 14, 17].
The main aim of our study was to determine the distribution 
of trisomy 21 cases in individual free β-hCG and PAPP-A MoM 
ranges. A detailed analysis indicated that most cases of trisomy 
Table 1. ROC analysis — (cut-off point, sensitivity, specificity, area under the curve — AUC, statistical significance level — p) PAPP-A MoM and 
β-hCG MoM for classifiers differentiating between participants with fetal trisomy 21 and normal fetal karyotype
Variable Cut-off point Sensitivity [%] Specificity [%] AUC p
PAPP-A MoM 0.463 70.8 50.0 0.63 0.013
β-hCGMoM 2.71 75.1 52.8 0.656 0.003
Figure 5. NT analysis for selected PAPP-A MoM ranges in participants 
with known fetal trisomy 21
Figure 6. NT analysis for selected bHCG MoM ranges in participants 
with known fetal trisomy 21
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Table 2. Atypical PAPP-A MoM, β-hCG MoM and NT in pregnant women with diagnosed fetal trisomy 21
No. PAPP-A MoM free B-hCG MoM NT Karyotype Double marker test risk estimate
1. 0.885 5.468 6 47, XY, + 21 1 : 2
2. 0.844 1.750 5.5 47, XY, + 21 1 : 12
3. 0.334 1.236 8 47, XY, + 21 1 : 2
4. 0.568 1.095 2.5 47, XX, + 21 1 : 108
5. 1.035 3.924 6.0 47, XX, + 21 1 : 2
6. 0.676 0.715 6 47, XX, + 21 1 : 3
7. 0.904 9.304 2.7 47, XX, + 21 1 :4
8. 0.782 1.895 4 47, XX, + 21 1 : 2
9. 0.947 2.714 8.6 47, XY, + 21 1 : 4
10. 0.915 1.858 2.5 47, XY, + 21 1 : 128
11. 0.973 0.788 4.8 47, XY, + 21 1 : 4
12. 0.837 2.053 4.2 47, XX, inv(9)(p12q13), + 21 1 : 4
13. 0.806 3.773 4 47, XY, + 21 1:4
14. 0.839 3.547 1.6 47, XX, + 21, 21 pss 1 : 29
15. 0.318 1.442 5 46, XX, der(14; 21)(q10; q10), + 21 1 : 2
21 detected during antenatal screening, as seen in previous 
studies, had free β-hCGMoM over 1.5 (85.28%), but only 53% 
of these had PAPP-A MoM below 0.5. The correlation of all 
components of the characteristics in the screening test for the 
risk of trisomy 21 (< 0.5 PAPP-A MoM and > 1.5 β-hCG MoM) 
and increased NT, occurred in only 23.5% of the pregnant 
women. In all cases with prenatally diagnosed 21 fetal trisomy, 
the evidence of risk was increased in the screening test. Our 
findings prove the benefit of antenatal screening in helping to 
identify high-risk cases for Down Syndrome [18].
The analysis of free β-hCG and PAPP-A MoM values in 
cases with known fetal trisomy 21 identified 53% (n-18) 
atypical cases with biochemical test results and their con-
figuration different from those typically seen in fetal trisomy 
21. The most common atypical configuration was a normal 
PAPP-A MoM (of approximately 1.0) combined with an el-
evated free β-hCGMoM (above 1.5). Most fetuses in this sub-
group presented with an increased NT. In such cases, the free 
β-hCGMoM and increased NT were the indicators of trisomy 
Table 3. Atypical PAPP-A and free β-hCG MoM values in pregnant 
women with confirmed fetal trisomy 21
PAPP-A and free β-hCGMoM 
value analysis 
No. of 
cases with 
trisomy 21
% of all trisomy 
21 cases detected 
antenatally 
normal PAPP-A MoM and free 
β-hCGMoM ≥ 1.5 13 38.2
PAPP-A MoM < 0.5 and normal 
free β-hCGMoM 3 8.8
decreased both PAPP-A MoM 
and free β-hCGMoM 1 2.9
normal PAPP-A MoM and 
decreased free β-hCGMoM 1 2.9
21. Furthermore, there were 2.9% cases with an atypical con-
figuration involving PAPP-A MoM below 0.5 combined with 
a normal free β-hCGMoM; and increased NT was demon-
strated in most of these fetuses. In the two remaining cases, 
the biochemical parameter MoM values were not indicative 
of trisomy 21. However, their abnormal concentrations and 
an increased NT indicated they were high risk and led to the 
ultimate confirmation of Down Syndrome in the fetuses. 
Additionally, we have analyzed in detail the nuchal trans-
lucency data in the selected free β-hCG and PAPP-A MoM 
ranges. Although the mean NT in a subgroup with known 
fetal trisomy 21 was 3.9 mm, which is consistent with pre-
viously reported findings [8, 9, 19], not all fetuses in this 
subgroup presented with an increased NT. In those latter 
cases, the elevated risk of trisomy 21 was primarily deter-
mined by abnormal maternal serum concentrations of free 
β-hCG and/or PAPP-A.
Our findings unequivocally indicate that none of the 
analyzed parameters on their own offers enough sensitivity 
to provide a conclusive finding of fetal trisomy 21. In our 
sample, there were cases of confirmed Down Syndrome 
with normal maternal serum concentrations of assessed 
biochemical parameters as well as those with normal NT. 
The analysis shows that maternal serum biochemical mark-
ers and ultrasound fetal screening are complementary and 
should not be considered separately in trisomy 21 diag-
nostics.
CONCLUSIONS
1. The analysis of maternal serum PAPP-A and free β-hCG 
levels along with ultrasound-based nuchal translucency 
measurement are independent of each other as param-
eters in trisomy 21 diagnostics.
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2. Assessing biochemical and ultrasound parameters in 
combination is an indispensable condition of assessing 
the risk of trisomy 21 occurrence in antenatal screening 
during the first-trimester.
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